Vir Biotechnology (NASDAQ:VIR) Stock Crosses Above Fifty Day Moving Average – Here’s What Happened

Vir Biotechnology, Inc. (NASDAQ:VIR)’s share price passed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $11.03 and traded as high as $12.45. Vir Biotechnology shares last traded at $12.21, with a volume of 1,887,037 shares.

Key Stories Impacting Vir Biotechnology

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Analyst sentiment improved: Needham raised its price target to $20 from $18 and maintained a Buy rating. Zacks Research also upgraded VIR from Strong Sell to Hold, reducing a bearish signal. Needham rating Zacks rating
• Positive Sentiment: Key clinical catalyst ahead: Vir plans to present topline Phase 3 ECLIPSE 1 results for elebsiran and tobevibart in chronic hepatitis delta at AASLD’s 2026 liver meeting. Positive data could be a meaningful catalyst, though the outcome is uncertain. AASLD data presentation
• Positive Sentiment: Cash runway extends into the second half of 2028, giving the company additional time to advance its pipeline and reach development milestones. Cash runway update
• Neutral Sentiment: Q3 loss beat expectations: Vir reported a loss of $0.57 per share, narrower than analysts’ expected loss of about $0.75–$0.80 and the $1.17 loss a year earlier. Q3 results
• Neutral Sentiment: An executive sold a small number of shares under a pre-arranged plan to cover tax withholding on vested equity awards; the stated purpose makes this less indicative of a change in outlook. SEC filing
• Negative Sentiment: Revenue missed sharply: Q3 revenue was negative $0.19 million versus analysts’ estimate of $0.98 million, and was down 178.3% year over year, tempering the earnings beat. Revenue results

Wall Street Analyst Weigh In

Several research analysts have weighed in on VIR shares. Wall Street Zen upgraded shares of Vir Biotechnology from a “hold” rating to a “buy” rating in a research report on Saturday. Zacks Research upgraded Vir Biotechnology from a “strong sell” rating to a “hold” rating in a research report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Friday, October 2nd. Morgan Stanley set a $25.00 target price on shares of Vir Biotechnology in a report on Thursday, August 6th. Finally, HC Wainwright upped their price objective on shares of Vir Biotechnology from $20.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, October 7th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $22.14.

Vir Biotechnology Price Performance

The company has a market cap of $2.07 billion, a price-to-earnings ratio of -9.69 and a beta of 1.70. The firm has a fifty day simple moving average of $11.03 and a 200 day simple moving average of $9.61.

Vir Biotechnology (NASDAQ:VIR) last released its earnings results on Wednesday, November 4th. The company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.18. The company had revenue of ($0.19) million for the quarter, compared to the consensus estimate of $0.98 million. The business’s revenue was down 178.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.17) EPS. Analysts expect that Vir Biotechnology, Inc. will post -1.84 earnings per share for the current year.

Insider Activity at Vir Biotechnology

In related news, EVP Vanina de Verneuil sold 2,407 shares of the business’s stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $11.10, for a total value of $26,717.70. Following the sale, the executive vice president directly owned 110,193 shares in the company, valued at $1,223,142.30. The trade was a 2.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 2.90% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new position in shares of Vir Biotechnology during the second quarter valued at approximately $210,712,000. ARCH Venture Management LLC purchased a new stake in shares of Vir Biotechnology during the second quarter worth $129,353,521. ADAR1 Capital Management LLC purchased a new stake in shares of Vir Biotechnology in the first quarter valued at about $24,593,000. Bank of America Corp DE acquired a new stake in Vir Biotechnology during the second quarter valued at approximately $11,642,000. Finally, Avidity Partners Management LP acquired a new stake in Vir Biotechnology during the first quarter valued at $8,512,000. Institutional investors own 65.32% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical-stage immunology company focused on developing medicines to prevent and treat serious infectious diseases and other immune-related conditions. The company uses antibody engineering, immunologic approaches and other technologies to identify and advance therapies designed to harness or modify the immune system.

Vir’s research and development programs have included treatments and vaccines for hepatitis B, human immunodeficiency virus (HIV), influenza and other infectious diseases.